WASHINGTON, Sept. 2 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to TXP Innovations LLC dba Tex Peptides from its Center for Drug Evaluation and Research:

* * *

Recipient: Felicia Romero, CEO, TXP Innovations LLC dba Tex Peptides, 539 West Commerce Street, Dallas, TX 75208-1953, United States, support@texpeptide.com, texpeptides@gmail.com

Issuing Office: Center for Drug Evaluation and R . . .

Click here for more information about our products